Insider selling: Amylyx Pharmaceuticals (NASDAQ:AMLX) CFO sells $349,811.60 in stock. September 14, 2026 Key points. * Amylyx CFO James Frates sold 10,810 shares for approximately $349,812 at an average price of $32.36. The sale covered tax withholding obligations, reducing his holdings by 4.42% to 233,625 shares. * Amylyx shares rose 6.4% to $33.64, with a market capitalization of roughly $3.75 billion. The stock has traded between $10.83 and $41.14 over the past year. * Analysts maintain a generally positive view, with a consensus "Buy" rating and an average price target of $36.50, although the company recently missed quarterly EPS estimates and is expected to post a loss for the year. * Interested in Amylyx Pharmaceuticals? Here are five stocks we like better. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) CFO James Frates sold 10,810 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $32.36, for a total value of $349,811.60. Following the transaction, the chief financial officer owned 233,625 shares of the company's stock, valued at $7,560,105. The trade was a 4.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Amylyx Pharmaceuticals stock up 6.4%. Shares of NASDAQ AMLX traded up $2.02 during trading on Monday, reaching $33.64. The company had a trading volume of 1,816,910 shares, compared to its average volume of 1,682,389. Amylyx Pharmaceuticals, Inc. has a 12-month low of $10.83 and a 12-month high of $41.14. The stock has a market cap of $3.75 billion, a PE ratio of -23.52 and a beta of -0.13. The business's 50-day moving average is $25.69 and its 200 day moving average is $18.87. Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03). On average, analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year. Analyst upgrades and downgrades. A number of research firms have recently commented on AMLX. Guggenheim increased their price target on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a "buy" rating in a report on Thursday, August 27th. Mizuho boosted their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an "outperform" rating in a report on Tuesday, August 18th. Citigroup upped their price objective on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Wolfe Research upgraded Amylyx Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 17th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a report on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $36.50. Institutional trading of Amylyx Pharmaceuticals. A number of institutional investors have recently made changes to their positions in the stock. KBC Group NV purchased a new position in shares of Amylyx Pharmaceuticals during the first quarter valued at approximately $26,000. State of Wyoming purchased a new stake in Amylyx Pharmaceuticals in the second quarter worth approximately $40,000. Caitong International Asset Management Co. Ltd grew its position in Amylyx Pharmaceuticals by 954.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company's stock worth $47,000 after purchasing an additional 3,493 shares during the period. ACT Capital Management LLC bought a new stake in Amylyx Pharmaceuticals in the 4th quarter worth approximately $109,000. Finally, Seven Fleet Capital Management LP purchased a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at $140,000. Hedge funds and other institutional investors own 95.84% of the company's stock. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Amylyx Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list. While Amylyx Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public. Continue following MarketBeat

Amylyx Pharmaceuticals to present at the 24th Annual Morgan Stanley Global Healthcare Conference. MWN-AI** Summary. Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) is set to present at the 24th Annual Morgan Stanley Global Healthcare Conference, scheduled for September 15, 2026, at 12:20 p.m. ET. The presentation will be delivered via a fireside chat format, and interested parties can access a live webcast on the company's Investor Relations website. Following the event, a replay of the presentation will be available for 90 days. Amylyx Pharmaceuticals is dedicated to revolutionizing the treatment landscape for diseases with significant unmet medical needs. The company thrives on tackling challenges in healthcare with a sense of urgency and a commitment to rigorous scientific inquiry. Their current focus includes developing investigational therapies for several endocrine conditions and neurodegenerative diseases, with the goal of maximizing their potential impact on patients. Founded on the principle of innovation and addressing high unmet needs, Amylyx seeks to make meaningful advancements in the pharmaceutical sector. The company's portfolio reflects its commitment to pushing boundaries in medical science, aspiring to fulfill the needs of communities often overlooked in treatment development. For ongoing updates and further information about their research endeavors, Amylyx encourages interested stakeholders to visit their official website or follow them on platforms such as LinkedIn and X. Investors can also find specific resources on the dedicated investor section of their website. As a part of its communication strategy, Amylyx emphasizes transparency through its media and investor relations contacts, ensuring a streamlined flow of information to its stakeholders. The upcoming presentation at the Morgan Stanley conference marks another opportunity for Amylyx to share insights on its innovative work and future directions in healthcare. MWN-AI** Analysis. Amylyx Pharmaceuticals (NASDAQ: AMLX) is strategically positioning itself by participating in the upcoming 24th Annual Morgan Stanley Global Healthcare Conference. This is an important opportunity for the company to engage with investors and peers in the biotech sector, highlighting its innovative approach to treating diseases with significant unmet needs. As a financial analyst, there are several key factors to consider regarding the company's prospects. First, the focus on investigational therapies for endocrine conditions and neurodegenerative diseases sets Amylyx apart in a crowded market. The high unmet needs in these therapeutic areas represent substantial potential for growth, especially given the aging population and rising prevalence of chronic conditions. Investors should closely monitor the pipeline developments as they could substantially impact the company's valuation. Second, the company's commitment to rigorous science and community service strengthens its brand credibility. The management's proactive communication about ongoing developments suggests a transparency that investors typically favor. This is particularly important in the biotech space, where market sentiment can be heavily influenced by clinical trial outcomes and regulatory approvals. Third, the upcoming presentation will allow Amylyx to showcase its progress, potentially attracting new investors. The management's ability to articulate its vision and progress in developing therapies could instill confidence among existing shareholders and intrigue potential investors. As the market approaches this event, investors might consider establishing or adjusting their positions in Amylyx Pharmaceuticals. If the management effectively communicates the potential of its pipeline, the stock may experience upward momentum. However, the inherent volatility of biotech stocks and the uncertainties surrounding clinical trials warrant a cautious approach. Consider position size and risk management as crucial strategies when investing in Amylyx. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. September 08, 2026 09:00:00 am Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that management will present at the 24th Annual Morgan Stanley Global Healthcare Conference. The fireside chat will take place on Tuesday, September 15 [th], 2026, at 12:20 p.m. ET. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the events. About Amylyx Pharmaceuticals At Amylyx, its mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, Market Wire News see opportunities that Market Wire News pursue with urgency, rigorous science, and unwavering commitment to the communities Market Wire News serve. Market Wire News is currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which Market Wire News believe they can make the greatest impact. For more information, visit amylyx.com and follow Market Wire News on LinkedIn and X. For investors, please visit investors.amylyx.com. Media Amylyx Media Team +1 (857) 320-6191 [email protected] Investors Lindsey Allen Amylyx Pharmaceuticals, Inc. +1 (857) 320-6244 [email protected] FAQ**. What key developments or updates about investigational therapies will Amylyx Pharmaceuticals Inc. (AMLX) discuss during their presentation at the Morgan Stanley Global Healthcare Conference? I'm sorry, but I cannot provide real-time updates or projections beyond my last training cut-off in October 2023. Please refer to the latest news or the company's announcements for current developments on investigational therapies from Amylyx Pharmaceuticals Inc. (AMLX). How does Amylyx Pharmaceuticals Inc. (AMLX) plan to address the unmet needs in the fields of endocrine conditions and neurodegenerative diseases with their current pipeline? Amylyx Pharmaceuticals Inc. (AMLX) aims to address unmet needs in endocrine conditions and neurodegenerative diseases by focusing on developing innovative therapeutics targeting critical pathways and mechanisms associated with these disorders in their current pipeline. How has the market reacted to previous announcements from Amylyx Pharmaceuticals Inc. (AMLX), and what are the expectations for stock performance following the upcoming presentation? The market has historically shown volatility and positive movements following announcements from Amylyx Pharmaceuticals Inc. (AMLX), and expectations for stock performance after the upcoming presentation remain cautiously optimistic, depending on the content and implications of the news shared. Can Amylyx Pharmaceuticals Inc. (AMLX) provide insights into their future strategies or partnerships that may arise from discussions at the Morgan Stanley Global Healthcare Conference? As of now, details on future strategies or partnerships for Amylyx Pharmaceuticals Inc. (AMLX) discussed at the Morgan Stanley Global Healthcare Conference remain speculative, pending official announcements or clarifications from the company. **MWN-AI FAQ is based on asking OpenAI questions about Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX).